The United States currently reports the highest autism prevalence of any large country, with the most recent CDC data putting the rate at 1 in 31 children (32.2 per 1,000) among 8-year-olds in 2022. That figure is more than four times the global average of roughly 1 in 127 people, estimated by the World Health Organization in 2021. But the gap between the U.S. and the rest of the world says as much about how countries detect and count autism as it does about how common the condition actually is.
Where the U.S. Numbers Come From
The CDC tracks autism through its Autism and Developmental Disabilities Monitoring Network, which pulls health and education records from 16 sites across the country. The latest report focused on children born in 2014 (aged 8 in 2022) and children born in 2018 (aged 4 in 2022). Eight-year-olds are used as the benchmark because most children who will receive a diagnosis have received one by that age.
The 1-in-31 figure represents a steady climb. In 2000, the CDC estimated 1 in 150 children had autism. By 2012 it was 1 in 69, and by 2020 it was 1 in 36. Each update has pushed the number higher, driven largely by broader diagnostic criteria, better screening tools, and increased awareness among parents and pediatricians rather than a simple surge in the underlying condition.
Other Countries With High Reported Rates
Several other wealthy nations report rates that approach or overlap with U.S. figures in specific studies. Qatar, the United Arab Emirates, South Korea, and Japan have all produced community-based studies showing prevalence above 2 percent in children, depending on the methodology used. A widely cited 2011 South Korean study found a rate of about 1 in 38 children when researchers actively screened an entire school district rather than relying on existing medical records.
Australia, Canada, and several northern European countries also report rates well above the global average, generally in the range of 1 in 50 to 1 in 70 children. These countries share something important: robust healthcare systems, established screening programs, and diagnostic frameworks that capture a wide spectrum of presentations.
Why Wealthier Countries Report Higher Rates
The pattern is consistent: the more resources a country devotes to developmental screening, the more autism it finds. This doesn’t mean autism is more common in rich countries. It means rich countries are better at identifying it. Data from the Global Burden of Disease Study, covering 1990 through 2019, illustrate this dynamic. High-income countries saw a 20 percent relative increase in autism incidence over that period, while low-income countries experienced a 114 percent absolute increase, largely because baseline detection was so low that even modest improvements in healthcare infrastructure produced dramatic jumps in reported cases.
In many low- and middle-income countries, children with autism may never encounter a clinician trained to recognize the condition. They may be classified under intellectual disability, behavioral problems, or receive no diagnosis at all. Sub-Saharan Africa and parts of South and Southeast Asia have reported prevalence rates below 1 in 500, figures that almost certainly reflect underdetection rather than a genuinely lower occurrence.
Diagnostic Criteria Vary by Country
Not every country uses the same rulebook for diagnosing autism. The United States relies on the DSM-5, published by the American Psychiatric Association, while most of the world uses the ICD system maintained by the World Health Organization. These systems have converged in recent years, but meaningful differences remain.
The DSM-5, adopted in 2013, collapsed several previously separate diagnoses (including Asperger’s syndrome and a broad “not otherwise specified” category) into a single autism spectrum disorder diagnosis. Under the older system, nearly five times as many people were placed in the vague “not otherwise specified” bucket as received a classic autism diagnosis. The consolidation was designed to improve consistency, but it also changed who qualifies. People who previously would have been labeled with Asperger’s or a borderline presentation now fall under the autism umbrella in countries using the DSM-5, while countries still using older ICD criteria may not capture those same individuals.
The ICD-10, still in use in many countries even as the ICD-11 rolls out, also treated autism and ADHD as mutually exclusive diagnoses. The DSM-5 removed that restriction, allowing both to be diagnosed in the same person. This single change can meaningfully shift prevalence figures in countries that adopt it.
The Gender Gap Is Narrowing
Autism has long been considered far more common in boys, with global estimates placing the male-to-female ratio somewhere between 2.7 and 4.1. That ratio is shrinking fast. A large Swedish population study tracking birth cohorts over more than 35 years found that by 2022, the cumulative male-to-female ratio for autism diagnoses had dropped to just 1.2 by age 20. For people born in 2000 and later who were older than 15, the ratio was at or below 1, meaning women and girls were being diagnosed at equal or higher rates than men and boys.
Projections from the same study suggested the ratio would reach full parity by 2024. This shift reflects improved recognition that autism often presents differently in girls and women, who are more likely to mask symptoms or be misdiagnosed with anxiety or mood disorders. As clinicians get better at recognizing these presentations, the overall prevalence numbers in countries with advanced diagnostic systems will continue to rise, not because more people are becoming autistic, but because more people who have always been autistic are finally being counted.
What the Numbers Actually Tell You
If you’re comparing countries, the headline number is less useful than understanding what’s behind it. A country reporting 1 in 31 children with autism and a country reporting 1 in 500 are not necessarily describing different realities. They may be describing different healthcare systems, different diagnostic traditions, and different levels of public awareness. The U.S. sits at the top of global prevalence tables primarily because it invests heavily in surveillance, uses broad diagnostic criteria, and has a culture of developmental screening that starts in pediatric well-child visits.
Countries with lower reported rates are not immune to autism. They are, in many cases, simply not yet equipped to find it. As screening infrastructure expands globally, the gap between high-income and low-income country estimates will likely continue to close, not because autism is spreading, but because the world is getting better at recognizing what has always been there.